Cárcamo-Calvo Roberto, Muñoz Carlos, Buesa Javier, Rodríguez-Díaz Jesús, Gozalbo-Rovira Roberto
Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibañez 17, 46010 Valencia, Spain.
Instituto de Investigación INCLIVA, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
Pathogens. 2021 Apr 26;10(5):520. doi: 10.3390/pathogens10050520.
Rotavirus is the leading cause of severe acute childhood gastroenteritis, responsible for more than 128,500 deaths per year, mainly in low-income countries. Although the mortality rate has dropped significantly since the introduction of the first vaccines around 2006, an estimated 83,158 deaths are still preventable. The two main vaccines currently deployed, Rotarix and RotaTeq, both live oral vaccines, have been shown to be less effective in developing countries. In addition, they have been associated with a slight risk of intussusception, and the need for cold chain maintenance limits the accessibility of these vaccines to certain areas, leaving 65% of children worldwide unvaccinated and therefore unprotected. Against this backdrop, here we review the main vaccines under development and the state of the art on potential alternatives.
轮状病毒是导致儿童严重急性胃肠炎的主要原因,每年造成超过128,500人死亡,主要发生在低收入国家。尽管自2006年左右首次引入疫苗以来死亡率已大幅下降,但估计仍有83,158例死亡可预防。目前使用的两种主要疫苗Rotarix和RotaTeq均为口服活疫苗,在发展中国家已被证明效果较差。此外,它们与肠套叠的轻微风险有关,并且需要冷链维护限制了这些疫苗在某些地区的可及性,导致全球65%的儿童未接种疫苗,因此得不到保护。在此背景下,我们在此回顾正在研发的主要疫苗以及潜在替代方案的最新进展。